Abstract:Abstract Lung cancer is the leading cause of cancer-related mortality. Detection of drug actionable genetic alterations has made the standard systemic therapy to a more personalized one including targeted therapy and immune checkpoint blockade. Despite the initial response, majority of patients develop resistance to treatment. Therefore, understanding the mechanisms of resistance as well as discovering novel cancer targets is necessary. Resistance to therapies can be associated with an existing clone of tumor cells with genetic alteration, or the emergence of cells with epigenetic changes overcoming the treatment-induced stress. Therefore, investigating the epigenetic aberrations that occur in tumor cells may reveal novel targetable markers that can be of great clinical significance. Methods: Organoid models established from non-small cell lung cancer (NSCLC) patient surgical resections and pleural effusion were dissociated into single cells and plated in matrigel-coated 384-well plate. A panel of 32 NSCLC organoid models were treated with a library of 41 epigenetic probes (1uM) and a DMSO control over a period of 8 days. Cell titre glo assay was performed to measure cell survival. Results: Arginine methyl transferase protein 5 (PRMT5) inhibited the cell growth of large proportion of the NSCLC organoid models. LLY-283 showed the most significant effect, with 50% of all organoid models (16/32) treated with LLY283 showing ≥50% reduction in cell viability. Further testing with multiple concentrations of several PRMT5 inhibitors revealed models with differential responses to PRMT5 inhibition. To investigate the differential gene expression changes induced by PRMT5 inhibition, we performed RNA-sequencing on three PRMT5 inhibitor sensitive and three resistant organoid models. Ongoing analyses aim at identifying differentially expressed genes in sensitive and resistant models in response to PRMT5 inhibition, and pathway enrichment analysis to determine the differential mechanisms of response to PRMT5 inhibition. Conclusion: Epigenetic drug screening on a large cohort of NSCLC organoid models reveals PRMT5 as potential novel therapeutic target in NSCLC. Further correlative analysis with transcriptomic changes induced by the PRMT5 inhibitors may reveal biomarkers of response. Citation Format: Khadija Jafarova, Quan Li, Nikolina Radulovich, Geoffrey Liu, Ming S Tsao. Screening non-small cell lung cancer patient-derived organoids with epigenetic probes reveals PRMT5 as an oncogenic target [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B026.

Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers

Development of an AlphaLISA High Throughput Technique to Screen for Small Molecule Inhibitors Targeting Protein Arginine Methyltransferases

Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-Yl)anilines Core Identified by Virtual Screening and Biological Evaluation.

Abstract 1808: Discovery of highly selective novel MTA-cooperative PRMT5 inhibitors for the treatment of cancers

SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders

Selective Small-Chemical Inhibitors of Protein Arginine Methyltransferase 5 with Anti-Lung Cancer Activity

Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1)

First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers

Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.

Abstract 4588: Combination of MTA-cooperative PRMT5 inhibitor and direct mutant-selective KRAS inhibitors as a novel therapeutic approach for MTAP-deficient pancreatic cancer

A chemical biology toolbox to investigate in-cell target engagement and specificity of PRMT5-inhibitors

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Medicinal chemistry insights into PRMT5 inhibitors

Abstract 1356: In vivo epigenetic CRISPR screen identifies PRMT5 as an immune suppressor in pancreatic cancer

Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.

Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

Design, Synthesis and Biological Evaluation of Novel and Potent Protein Arginine Methyltransferases 5 Inhibitors for Cancer Therapy

Abstract B026: Screening non-small cell lung cancer patient-derived organoids with epigenetic probes reveals PRMT5 as an oncogenic target

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers